Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival

By afschroeder • March 11, 2026

Marsh LA, Kim TH, Zhang M, Kubalanza K, Treece CL, Chase D, Memarzadeh S, Salani R, Karlan B, Rao J, Konecny GE. Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival. Gynecol Oncol. 2023 Oct;177:173-179. doi: 10.1016/j.ygyno.2023.09.002. Epub 2023 Sep 14. PMID: 37716223.

Tags: Chemotherapy response score, Hematology/Oncology, Neoadjuvant chemotherapy, ovarian cancer, Publications

Lentivirus-Based Hematopoietic Stem/Progenitor Cell Therapy Provides Effective and Long-Term Treatment in Hypophosphatasia Mouse Model

Carrillo M, Tomer S, Wang L, Cook E, Wennerberg W, Tien N, Ng H, Alagarsamy J, Rezek V, Martin H, Narisawa S, Millan JL, Crine[...]

Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care

Brufsky AM, Finn RS, Metzger O, Goncalves R, Huang-Bartlett C, Sreenivasan S, Nur U, Davies J, Grigorenko A, Long GH. Comparative effectiveness of CDK4/6 inhibitors[...]

Phase II study of magrolimab combination therapies in patients with head and neck squamous-cell carcinoma

Colevas AD, Chin V, Park JJ, Adkins D, Phan M, Fang B, Forget F, Amorim J, Misiukiewicz K, Costa DA, Rainey N, Even C, Wong[...]